Overview

An Open Label, Safety Study to Assess the Potential for Adrenal Suppression.

Status:
Completed
Trial end date:
2017-12-12
Target enrollment:
Participant gender:
Summary
An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Following Treatment with DSXS in Patients with Atopic Dermatitis
Phase:
Phase 2
Details
Lead Sponsor:
Taro Pharmaceuticals USA